JP2018526345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526345A5 JP2018526345A5 JP2018504281A JP2018504281A JP2018526345A5 JP 2018526345 A5 JP2018526345 A5 JP 2018526345A5 JP 2018504281 A JP2018504281 A JP 2018504281A JP 2018504281 A JP2018504281 A JP 2018504281A JP 2018526345 A5 JP2018526345 A5 JP 2018526345A5
- Authority
- JP
- Japan
- Prior art keywords
- cycloserine
- composition
- therapeutic agent
- salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 1
- 229960001157 acamprosate calcium Drugs 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103459A JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200864P | 2015-08-04 | 2015-08-04 | |
| US62/200,864 | 2015-08-04 | ||
| PCT/US2016/045547 WO2017024129A1 (en) | 2015-08-04 | 2016-08-04 | Combination therapy using acamprosate and d-cycloserine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103459A Division JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526345A JP2018526345A (ja) | 2018-09-13 |
| JP2018526345A5 true JP2018526345A5 (enExample) | 2019-09-19 |
Family
ID=57944041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504281A Pending JP2018526345A (ja) | 2015-08-04 | 2016-08-04 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
| JP2021103459A Pending JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103459A Pending JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180221315A1 (enExample) |
| EP (1) | EP3331518A4 (enExample) |
| JP (2) | JP2018526345A (enExample) |
| KR (1) | KR20180034442A (enExample) |
| AU (2) | AU2016303610A1 (enExample) |
| CA (1) | CA2993614A1 (enExample) |
| HK (1) | HK1255584A1 (enExample) |
| IL (1) | IL257035A (enExample) |
| SG (1) | SG10201914045QA (enExample) |
| WO (1) | WO2017024129A1 (enExample) |
| ZA (1) | ZA201800558B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018526345A (ja) * | 2015-08-04 | 2018-09-13 | コンフルーエンス ファーマシューティカルズ，エルエルシー | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
| AU2018269557B2 (en) | 2017-05-17 | 2021-06-03 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
| BR112019024817A2 (pt) | 2017-05-25 | 2020-08-18 | Glytech Llc. | formulações para tratamento de distúrbio de estresse pós-traumático |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| JP2025069475A (ja) * | 2022-03-08 | 2025-05-01 | ソシウム株式会社 | Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤 |
| JP7660827B2 (ja) * | 2023-04-27 | 2025-04-14 | ソシウム株式会社 | 筋萎縮性側索硬化症の治療又は予防剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1073432E (pt) * | 1998-04-14 | 2007-10-22 | Gen Hospital Corp | Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US9308260B2 (en) * | 2007-07-05 | 2016-04-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Anticonvulsive pharmaceutical compositions |
| US9463172B2 (en) * | 2009-02-12 | 2016-10-11 | Indiana University Research & Technology Corporation | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
| US20100216805A1 (en) * | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| JP5893135B2 (ja) * | 2011-06-28 | 2016-03-23 | ビボゾーン インコーポレイテッド | 多重ターゲッティングの相乗効果を誘発する有効物質の組合せ及びその用途 |
| WO2016179252A1 (en) * | 2015-05-04 | 2016-11-10 | Confluence Pharmaceuticals, Llc | Sprinkle formulations of acamprosate |
| JP2018526345A (ja) * | 2015-08-04 | 2018-09-13 | コンフルーエンス ファーマシューティカルズ，エルエルシー | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
-
2016
- 2016-08-04 JP JP2018504281A patent/JP2018526345A/ja active Pending
- 2016-08-04 CA CA2993614A patent/CA2993614A1/en not_active Abandoned
- 2016-08-04 US US15/749,705 patent/US20180221315A1/en not_active Abandoned
- 2016-08-04 SG SG10201914045QA patent/SG10201914045QA/en unknown
- 2016-08-04 AU AU2016303610A patent/AU2016303610A1/en not_active Abandoned
- 2016-08-04 WO PCT/US2016/045547 patent/WO2017024129A1/en not_active Ceased
- 2016-08-04 EP EP16833870.5A patent/EP3331518A4/en not_active Withdrawn
- 2016-08-04 KR KR1020187002542A patent/KR20180034442A/ko not_active Ceased
- 2016-08-04 HK HK18114711.9A patent/HK1255584A1/zh unknown
-
2018
- 2018-01-21 IL IL257035A patent/IL257035A/en unknown
- 2018-01-26 ZA ZA201800558A patent/ZA201800558B/en unknown
-
2020
- 2020-06-02 US US16/890,533 patent/US20200360316A1/en not_active Abandoned
-
2021
- 2021-06-22 JP JP2021103459A patent/JP2021152060A/ja active Pending
-
2022
- 2022-04-01 AU AU2022202218A patent/AU2022202218A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526345A5 (enExample) | ||
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| JP2018520189A5 (enExample) | ||
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| JP2018514544A5 (enExample) | ||
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| BR112015010396A2 (pt) | terapia de combinação | |
| JP2015519404A5 (enExample) | ||
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2018516906A5 (enExample) | ||
| GB201021104D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| JP2012523437A5 (enExample) | ||
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| JP2018515506A5 (enExample) | ||
| SI2413933T1 (en) | 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN | |
| DK2091942T3 (da) | Substituerede pyrazinderivater til anvendelse som en medicin | |
| RU2009131745A (ru) | Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| NZ589618A (en) | PAEDIATRIC COMPOSITIONS COMPRISING 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol FOR TREATING MULTIPLE SCLEROSIS | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases |